Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997

Abstract

A joint Task Group of ICRP Committees 2 (Doses from Radiation Exposures) and 3 (Protection in Medicine; lead Committee for this report) has prepared a compilation of data on radiation dose to patients from radiopharmaceuticals.

The report provides biokinetic models, absorbed doses, and effective doses, using ICRP Publication 60 dosimetry, for 10 new radiopharmaceuticals: [Methyl-¹¹C]thymidine; [2-¹¹C]thymidine; ¹⁴C urea (incl. carbon dioxide and bicarbonate); ¹⁵O water; ^99mTc HIG, Pertechnegas, Technegas, and tetrofosmin; and ¹¹¹In HIG and octreotide.

It also provides recalculated dose data for the 19 most frequently used radiopharmaceuticals from ICRP Publication 53, using ICRP Publication 60 dosimetry, viz. ¹⁸F FDG; ⁵¹Cr EDTA; ⁶⁷Ga citrate; ⁷⁵Se SeHCAT; ^99mTc DMSA, DTPA, RBC, IDA, large colloids, WBC, MAA, non-absorbable markers, pertechnetate, and phosphates and phosphonates; ¹²³I Hippuran and MIBG; ¹³¹I Hippuran and NP59; and ²⁰¹Tl thallous ion. Printing errors detected in ICRP Publication 53 are also listed.

Furthermore, the report reproduces with minor corrections and updates, and therefore supersedes, the information on 6 radiopharmaceuticals given in Addendum 1 to ICRP Publication 53: ³H neutral fat and fatty acids; ¹⁴C neutral fat and fatty acids; ⁶⁸Ga EDTA; and ^99mTc HM-PAO, MAG3, and MIBI.

There is an integrated index to all radiopharmaceuticals treated in ICRP publications so far, including a listing of effective doses per unit activity administered to adults.

This issue of the Annals of the ICRP also includes an Addendum to ICRP Publication 72 concerning age-dependent doses to members of the public from intakes of radionuclides.